|
Santaris Pharma at a glance |
|
|
|
|
|
|
Address: |
Santaris Pharma A/S
Kogle allé 6
DK 2970 Hørsholm
Tel: +45 45179800
Fax: +45 45179887
e-mail: info@santaris.com
www.santaris.com |
|
|
|
Santaris Pharma A/S
12626 High Bluff Drive Suite 440
San Diego CA 92130
TEL: (1) 858 764 7064 |
|
|
|
|
President and CEO |
Søren Tulstrup |
|
|
|
|
Management |
Henrik Ørum,
VP and CSO |
|
|
Henrik Stage,
VP and CFO |
|
|
Troels Koch,
VP and CTO |
|
|
Art Levin,
VP, President US Operations and CDO |
|
|
Bolette Wildt,
VP HR and Legal Affairs |
|
|
Stu Mackey
VP and BDO |
|
Mark Wedel
VP and CMO |
|
|
|
|
Chairman of the Board |
Flemming Ørnskov,
President Pharmaceuticals and OTC, Bausch & Lomb, Inc. |
|
|
|
|
Board Members |
Claus Bræstrup,
Chairman of the Board Life Cycle Pharma |
|
|
Søren Carlsen,
Managing Partner, Novo A/S, Venture Research |
|
|
Edwin de Graaf,
Managing Director and General Partner, Gilde Healthcare Partners |
|
|
Anders Hinsby
Partner, BankInvest Biomedical Venture |
|
|
Martien van Osch,
Managing Partner, Forbion Capital Partners |
|
|
Holger Reithinger,
Partner, Global Life Science Ventures |
|
|
Walther Wenninger,
Chairman of the Board of Paion AG, Aachen and Noxon Pharma AG, Berlin, Vice Chairman of Axiogenesis AG, Cologne |
|
|
|
|
Investors |
BankInvest
Forbion Capital Partners
Global Life Science Ventures GmbH
InnovationsKapital
Lønmodtagernes Dyrtidsfond (LD)
Novo A/S
Seventure Partners
Sunstone Capital A/S
Teknoinvest AS
Wyeth |
|
|
|
|
Pharmaceutical Partners |
Enzon Pharmaceuticals
GlaxoSmithKline
Wyeth Pharmaceuticals (now part of Pfizer)
Shire plc |
|
|
|
|
Number of staff |
+65 |
|
|
|
|
Technology Platform |
Santaris Pharma a/s is building a global business based on its proprietary Locked Nucleic Acid (LNA) Drug Platform and efficient Drug Discovery Engine developing innovative drugs targeting RNAs with the potential to meet significant unmet medical needs. RNA-targeting therapeutics is the most direct way to translate the genomic information into drugs, and LNA is the chemistry of choice for these applications. |
|
|
|
|
Therapeutic areas |
Metabolic disorders (own research and development)
Viral diseases (own discovery and development plus partnered)
Cancer (discovery and partnered projects)
Rare genetic disorders (partnered projects)
Other therapeutic areas (partnered projects) |
|
|
|
|
Mission statement |
Santaris Pharma A/S is an international clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies.
The Company’s proprietary Locked Nucleic Acid (LNA) Drug Platform, in combination with its highly specialized and targeted drug development capabilities, offers potential partners pre-screened drug candidates for commercial consideration across a multitude of disease states.
Santaris Pharma A/S research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases.
Santaris Pharma A/S, founded in 2003, is privately-held and headquartered in Denmark with operations in the US. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs.
The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceuticals (now part of Pfizer) and Shire plc. |
|
|